Phase II clinical trial of intra-lesional administration of TG1042 (adenovirus-interferon-gamma) in patients with relapsing primary cutaneous B-cell lymphomas.
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2014
At a glance
- Drugs TG 1042 (Primary)
- Indications Cutaneous B-cell lymphoma
- Focus Therapeutic Use
- Sponsors Transgene
- 07 Dec 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov record.
- 20 Dec 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 11 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.